Rituximab

Rituximab is a type of medicine called an antibody. It helps the body fight certain types of cancer, like leukemia and lymphoma. It works by targeting a specific protein on cancer cells.

Brand names:Mabthera, Rituxan, Truxima, Ruxience
Medication

What people taking Rituximab report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Diffuse Large B-Cell Lymphoma?

NameHow it went

About Rituximab

What It's For

Rituximab is a prescription biologic medicine, a lab-made antibody, used to treat certain blood cancers and several autoimmune diseases. The original brand is Rituxan (sold as MabThera in Europe). Three biosimilars, Truxima, Ruxience and Riabni, are approved in the US as highly similar versions of the same antibody. In cancer care, rituximab treats adults with B-cell non-Hodgkin lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma, and chronic lymphocytic leukemia (CLL). It is often given together with chemotherapy. In follicular lymphoma it can also be used on its own, or continued as maintenance treatment after a good response to help keep the disease in check. Rituxan is also approved, alongside chemotherapy, for children 6 months and older with certain aggressive B-cell lymphomas and B-cell leukemia. For autoimmune disease, rituximab is approved for adults with moderate to severe rheumatoid arthritis, together with methotrexate, when a TNF blocker (another type of biologic arthritis medicine) has not worked well enough. It also treats granulomatosis with polyangiitis and microscopic polyangiitis, two forms of vasculitis in which inflammation damages blood vessels and organs such as the heart and lungs, in adults and children 2 and older, alongside steroids. Rituxan is approved for moderate to severe pemphigus vulgaris, an autoimmune disease that causes painful blisters on the skin and inside the mouth. Doctors also use rituximab off-label for some other immune conditions, such as multiple sclerosis.

How It Works

B cells are white blood cells that make antibodies. Most mature B cells carry a protein on their surface called CD20. Rituximab is an antibody designed to latch onto CD20, which marks the cell for destruction by the immune system. In B-cell lymphomas and CLL, the cancer cells carry CD20 too, so rituximab removes them along with normal B cells. In autoimmune diseases, B cells help drive the immune attack, for example by producing autoantibodies (antibodies aimed at the body's own tissue) and by activating other immune cells. Clearing them out can calm that attack. B cells in the blood drop within a few weeks of treatment and usually stay low for at least six months. They then return gradually; in lymphoma studies, levels were typically back to normal about a year after treatment ended, though a small number of people stay depleted much longer.

Dosage & Administration

Rituximab is given as an infusion into a vein (IV) at an infusion center or hospital, by staff equipped to manage severe reactions. It is not a medicine people take at home. Before each infusion, people usually receive acetaminophen and an antihistamine to reduce reactions, and those treated for rheumatoid arthritis, vasculitis or pemphigus also get an IV steroid. The first infusion is started slowly and sped up step by step if it goes well, so it typically takes several hours. Later infusions can usually start faster. The schedule depends on the condition. In lymphoma and CLL, doses are based on body size and timed with chemotherapy cycles or a maintenance plan. In rheumatoid arthritis, one course is two infusions two weeks apart, usually repeated every 24 weeks (about six months) depending on how the disease is doing, and no sooner than every 16 weeks. In vasculitis, treatment for active disease is typically one infusion a week for four weeks, followed by maintenance doses every six months once the disease is under control. Rituxan Hycela is a form given as an injection under the skin of the abdomen, which takes about five to seven minutes. It combines rituximab with hyaluronidase, an enzyme that helps the larger volume absorb. It is used only for adults with follicular lymphoma, diffuse large B-cell lymphoma or CLL, and only after at least one full IV dose of rituximab has been given without a severe reaction.

Side Effects

Infusion reactions are the most common problem, especially with the first dose. In lymphoma trials, about three in four people had some reaction during the first infusion, and reactions became less frequent with each later one. Typical signs are fever, chills or shaking, itching, rash or hives, nausea, headache, dizziness and changes in blood pressure, usually starting within the first one to two hours. Staff slow or pause the infusion and give medicines, and most reactions settle. Tell the nurse straight away about any new symptom during an infusion. Rarely, reactions are severe, with swelling of the face or throat, breathing trouble, chest pain or an irregular heartbeat, and most fatal reactions have happened with the first infusion. If breathing trouble or swelling of the face or throat starts after you have left the clinic, call 911. Beyond the infusion day, common effects depend on the condition and the medicines given alongside rituximab. People treated for lymphoma often have fever, tiredness and low white blood cell counts. People with rheumatoid arthritis most often have colds, sinus or chest infections and urinary tract infections. Because rituximab lowers immune defenses for months, serious bacterial, viral and fungal infections can occur during and after treatment. Contact the care team promptly for fever, flu-like symptoms, a painful red wound or burning when urinating. Call right away about painful mouth sores, blisters or peeling skin, which can signal a rare but severe skin reaction, and about severe belly pain or repeated vomiting, which can rarely mean a bowel blockage or tear in people also receiving chemotherapy.

Interactions & Warnings

Rituximab carries an FDA boxed warning, the agency's strongest, covering four risks: severe infusion reactions (described above), severe skin reactions, hepatitis B reactivation, and a brain infection called PML. Hepatitis B can stay dormant in the body for years, even in people who seem to have recovered from it. Rituximab can reawaken it, sometimes causing severe liver damage or liver failure. Everyone has a blood test for hepatitis B before starting, and people with signs of current or past infection are monitored closely and may be offered antiviral medicine. Reactivation has been reported up to two years after the last dose, so worsening tiredness or yellowing of the skin or eyes should be reported to the care team right away. PML (progressive multifocal leukoencephalopathy) is a rare, often fatal brain infection caused by a common virus that a healthy immune system keeps in check. Most cases have occurred in people who were also receiving chemotherapy or other immune-suppressing treatment, usually within a year of the last infusion. New confusion, loss of balance, trouble speaking or walking, weakness on one side of the body or vision problems need prompt contact with the care team. Vaccines need planning. Live vaccines are not recommended before or during treatment, and other vaccines may work less well while B cells are depleted, so the team will try to bring vaccinations up to date at least four weeks before a course begins. Taking rituximab with other immune-suppressing medicines adds to infection risk, and in rheumatoid arthritis there is little safety information on combining it with biologics other than methotrexate. Rituximab can harm a developing baby by depleting the baby's B cells. Effective contraception is advised during treatment and for 12 months after the last dose, and breastfeeding is not recommended during treatment and for 6 months afterward. People with a history of heart rhythm problems or angina (chest pain from reduced blood flow to the heart) are monitored more closely during infusions.

What to Expect

Infusion days take time, especially the first, so plan for a long visit. Reactions are most likely the first time and usually become milder with later doses. Blood counts are checked before treatment and during it, and are followed after the final dose until any low counts recover. How benefit is judged depends on the condition. In lymphoma and CLL, rituximab is part of a planned course, often alongside chemotherapy cycles, and the team tracks response with scans and blood tests. In rheumatoid arthritis, vasculitis and pemphigus, the team assesses symptoms and disease activity at follow-up visits, and further courses are timed by that assessment rather than by the calendar alone. The effect on the immune system outlasts the infusions. Because B cells stay low for at least six months, and antibody levels can fall, the higher risk of infection continues after the last dose, and some infections have been linked to antibody levels that stay low for many months. Keeping the care team informed about fevers and infections, and checking with them before any vaccine or new immune-suppressing medicine, remains important for as long as the effects last.

Questions to Ask Your Doctor

  1. 1.Will I receive Rituxan or a biosimilar, and is the under-the-skin form an option for me?
  2. 2.How long will my infusions take, and what happens if I have a reaction?
  3. 3.What did my hepatitis B test show, and do I need monitoring or antiviral medicine?
  4. 4.Which vaccines should I get before starting, and which should I avoid during and after treatment?
  5. 5.How long will my infection risk stay higher, and which symptoms should prompt a call?

Last reviewed • Oct 2026

Educational content, not medical advice.